Does 1 + Beat 2 +? And ADC-After-ADC

Category - Enhertu

DB-11 or DB-05 First? The DESTINY-Breast Sequencing Debate

ADC After ADC: Is It Worth It?

Why Moving T-DXd to the Curative Setting Matters

DB-05 and T-DM1 Limitations: Why T-DXd Demands the Redefinition of HER2 Assays

First-Line T-DXd vs. Cape? The Decision for Endocrine-Resistant HR+ Disease Based on DB-06 Data

T-DXd in Early-Stage HER2+: What Should Be Your ILD Monitoring Threshold?

Managing T-DXd-Associated ILD: Strategies for Vigilance and Low Threshold Intervention

Dr. Gregory Vidal and Dr. Erika Hamilton – What DB-05 & DB-11 Mean for Patients

T-Dxd Role in HER2-Low: Establishing the First Cytotoxic Line After Endocrine Therapy Failure

Analyzing the role of T-Dxd in DB06 HER2-low and HER2-ultralow advanced breast cancer

Bridging PATINA and DB09: The Evolving Induction Followed by Maintenance Strategy

DB09: T-DXd + Pertuzumab Challenges the Cleopatra Regimen in First-Line Metastatic Disease